惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

C
Check Point Blog
有赞技术团队
有赞技术团队
博客园 - 三生石上(FineUI控件)
博客园_首页
博客园 - 【当耐特】
WordPress大学
WordPress大学
月光博客
月光博客
博客园 - 叶小钗
S
SegmentFault 最新的问题
雷峰网
雷峰网
H
Help Net Security
宝玉的分享
宝玉的分享
A
About on SuperTechFans
IT之家
IT之家
J
Java Code Geeks
Hugging Face - Blog
Hugging Face - Blog
D
DataBreaches.Net
酷 壳 – CoolShell
酷 壳 – CoolShell
博客园 - 聂微东
T
The Blog of Author Tim Ferriss
B
Blog
freeCodeCamp Programming Tutorials: Python, JavaScript, Git & More
H
Hackread – Cybersecurity News, Data Breaches, AI and More
Y
Y Combinator Blog

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call...
SA Transcripts · 2026-05-06 · via All Articles on Seeking Alpha

Q1: 2026-05-05 Earnings Summary

EPS of -$0.83 beats by $0.03

 | 

Revenue of

$60.11M

(83.81% Y/Y)

beats by $4.04M

Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2026 Earnings Call May 5, 2026 8:00 AM EDT

Company Participants

David Connolly - Head of Investor Relations & Corporate Communications
David Meeker - Chairman, President & CEO
Jennifer Chien - Executive VP & Head of North America
Yann Mazabraud - Executive VP & Head of International
Hunter Smith - CFO & Treasurer

Conference Call Participants

Philip Nadeau - TD Cowen, Research Division
Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division
Derek Archila - Wells Fargo Securities, LLC, Research Division
Yuchen Ding - Jefferies LLC, Research Division
Corinne Jenkins - Goldman Sachs Group, Inc., Research Division
Michael Ulz - Morgan Stanley, Research Division
Seamus Fernandez - Guggenheim Securities, LLC, Research Division
Samantha Semenkow - Citigroup Inc., Research Division
Joseph Stringer - Needham & Company, LLC, Research Division
Lisa Walter - RBC Capital Markets, Research Division

Presentation

Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Rhythm Pharmaceuticals First Quarter 2026 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to turn the conference over to Dave Connolly.

David Connolly
Head of Investor Relations & Corporate Communications

Thank you, Michelle. I'm Dave Connolly here at Rhythm Pharmaceuticals. For those of you participating on the conference call, our slides can be accessed and controlled by going to the Investors section of our website, ir.rhythmtx.com.

This morning, we issued our press release that provides first quarter 2026 financial results and a business update, and that press release is available on our website. Our agenda is listed on Slide 2.

On the call today are David Meeker, Chairman, Chief Executive Officer and President; Jennifer Lee, Executive Vice President, Head of North America; Hunter Smith, Chief Financial Officer; and Yann Mazabraud, Executive Vice President, Head of International, who is on the line joining us from Europe.